Laser ablation versus radiofrequency ablation for benign non-functioning thyroid nodules: twelve-month results of a randomized, parallel-arm, open-label trial

2021 ◽  
Author(s):  
Roberto Cesareo ◽  
Silvia Manfrini ◽  
Valerio Pasqualini ◽  
Cesare Ambrogi ◽  
Gianfranco Sanson ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Laser Ablation ◽  
Thyroid Nodules ◽  
Open Label ◽  
Open Label Trial

scholarly journals Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial)

Thyroid ◽  
2020 ◽  
Vol 30 (6) ◽  
pp. 847-856 ◽  
Author(s):  
Roberto Cesareo ◽  
Claudio Maurizio Pacella ◽  
Valerio Pasqualini ◽  
Giuseppe Campagna ◽  
Mario Iozzino ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Laser Ablation ◽  
Thyroid Nodules ◽  
Open Label ◽  
Open Label Trial

Llaser ablation vs radiofrequency ablation for benign non-functioning thyroid nodules: six-month results of a randomised, parallel, open-label, trial (LARA trial)

2020 ◽  
Author(s):  
Roberto Cesareo ◽  
Pacella Claudio Maurizio ◽  
Valerio Pasqualini ◽  
Giuseppe Campagna ◽  
Pantano Angelo Lauria ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Thyroid Nodules ◽  
Open Label ◽  
Open Label Trial

scholarly journals Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA)

2016 ◽  
Vol 33 (3) ◽  
pp. 295-299 ◽  
Author(s):  
Giovanni Mauri ◽  
Luca Cova ◽  
Cristian Giuseppe Monaco ◽  
Luca Maria Sconfienza ◽  
Sabrina Corbetta ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Laser Ablation ◽  
Thyroid Nodules ◽  
Percutaneous Laser Ablation ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

scholarly journals OR18-07 Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomised, Parallel, Open-Label, Trial (Lara Trial)

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Roberto Cesareo ◽  
Claudio Maurizio Pacella ◽  
Valerio Pasqualini ◽  
Giuseppe Campagna ◽  
Mario Iozzino ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Thyroid Nodules ◽  
Volume Reduction ◽  
High Rate ◽  
Open Label ◽  
Significant Difference ◽  
Nodule Volume ◽  
The Difference ◽  
Receive Treatment ◽  
One Year

Abstract ABSTRACT Background: Up to now, there are no direct prospective studies comparing Laser (LA) and radiofrequency ablation (RFA). We aimed to compare, in a head- to-head clinical trial, the efficacy and safety of both techniques in a population affected by solid or predominantly solid benign non-functioning thyroid nodules (BNTN). Methods. LARA is a six-month, single-use, randomized, superiority, open-label, parallel trial. We enrolled subjects with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems or patients without symptoms who experienced a volume increase >20% in one year. Nodules underwent core needle biopsy (CNB) to evaluate the histological architecture. Patients were randomly assigned (1:1) to receive treatment with either LA or RFA. The primary endpoint was to evaluate the difference in nodule volume reduction between the RF and the LA group at six months. Moreover, we aimed to assess the differences between groups in the rate of nodules with greater than 50% base volume reduction (successful rate) at six months after treatment. ClinicalTrials.gov: number NCT02714946. Findings: From January 2016 to November 2018, 60 patients were randomly assigned (30 participants per group). In the whole study population, the average volume of nodules was 25 ml. The two groups were similar in terms of basal nodule volume, thyroid function, histology, symptoms/cosmetic score and procedure time. At six months, participants in the RFA group showed a reduction volume of 64·3% (95% CI: 57·5% - 71·2%) compared to 53·2% (95% CI: 47·2% - 59·2%) in the LA group (p= 0·015) and this difference was also confirmed in a linear regression model adjusted for age, baseline volume and proportion of cellular component (Laser vs. RFA percent change Delta= -12·8, P=0·018).We have not recorded any significant difference in terms of successful rate at six months after treatment between the two groups (86·7% in the RFA vs 66·7% in the LA, p=0·127). At six months, both symptoms and cosmetic scores improved (compressive symptom score: 2·13 vs 3·9 for RFA, p < 0·001; 2·4 vs. 3·87 for LA, p < 0·001; cosmetic score: 1·65 vs 2·2 for RFA p <0·001, 1·85 vs 2·2 for LA p <0·001) without any statistically significant difference between the two groups. No statistical difference between the two groups was detected at six months as regards the TSH level. High rate of cellularity negatively affects the volume reduction in RFA group (r coefficient -0·41, p=0·034) while histological features did not affect the efficacy of the LA. The adverse event rates were 37% and 43% for RFA and LA, respectively, with no requirement for hospitalization. Interpretation: Both techniques are very effective in reducing the volume of thyroid nodules. RFA appears to be more effective than LA, but both techniques showed no difference in terms of success rate six months after treatment. The safety of the two techniques is very satisfactory.

Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules: 12-Month Results of a Randomized Trial (LARA II Study)

2021 ◽  
Author(s):  
Roberto Cesareo ◽  
Silvia Manfrini ◽  
Valerio Pasqualini ◽  
Cesare Ambrogi ◽  
Gianfranco Sanson ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Laser Ablation ◽  
Success Rate ◽  
Thyroid Nodules ◽  
Reduction Rate ◽  
Volume Reduction ◽  
Technical Success ◽  
Technical Success Rate ◽  
Nodule Volume

Abstract Context Radiofrequency ablation (RFA) seems to achieve a significantly larger nodule volume reduction rate (VRR) than laser ablation (LA) in benign nonfunctioning thyroid nodules (BNTNs) Objective To compare the efficacy and safety of both treatments at 12-month follow-up in patients with solid or predominantly solid BNTN. Methods This was a single-center, 12-month, randomized, superiority, open-label, parallel-group trial conducted in an outpatient clinic. Sixty patients with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems were randomly assigned (1:1 ratio) to receive either a single session of RFA or LA. Twenty-9 patients per group completed the study. The main outcome measures were VRR and proportion of nodules with more than 50% reduction (technical success rate). Results At 12 months, VRR was 70.9 ± 16.9% and 60.0 ± 19.0% in the RFA and LA groups, respectively (P = .024). This effect was confirmed in the linear regression model that was adjusted for age, sex, nodule baseline volume, and proportion of cellular components (RFA treatment: β = .390; P = .009). No significant between-group difference was observed in the technical success rate at 12 months after treatment. A statistically significant improvement was observed from the baseline to the 12-month follow-up for compression (RFA: 4.6 ± 2.6 and 1.3 ± 0.8, P < .001; and LA: 4.6 ± 2.1 and 1.6 ± 0.8, respectively, P < .001) and cosmetic (RFA: 3.4 ± 0.6 and 1.3 ± 0.5, P < .001; and LA: 3.4 ± 0.5 and 1.4 ± 0.6, P < .001) scores although the between-group differences were not significant. Conclusion RFA achieved a significantly larger nodule volume reduction at 12 months; however, the technical success rate was similar in the RFA and LA groups.

scholarly journals Use of Radiofrequency Ablation in Benign Thyroid Nodules: A Literature Review and Updates

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Kai-Pun Wong ◽  
Brian Hung-Hin Lang
Keyword(s):  
Radiofrequency Ablation ◽  
Laser Ablation ◽  
Thermal Ablation ◽  
Thyroid Nodules ◽  
Kidney Tumors ◽  
Ethanol Ablation ◽  
Efficient Treatment ◽  
Benign Thyroid Nodules ◽  
Cold Thyroid Nodules ◽  
Benign Thyroid

Successful thermal ablation using radiofrequency has been reported in various tumors including liver or kidney tumors. Nonsurgical minimally invasive ablative therapy such as radiofrequency ablation (RFA) has been reported to be a safe and efficient treatment option in managing symptomatic cold thyroid nodules or hyperfunctioning thyroid nodules. Pressure and cosmetic symptoms have been shown to be significantly improved both in the short and long terms after RFA. For hyperfunctioning thyroid nodules, RFA is indicated for whom surgery or radioiodine are not indicated or ineffective or for those who refuse surgery or radio-iodine. Improvement of thyroid function with decreased need for antithyroid medications has been reported. Complication rate is relatively low. By reviewing the current literature, we reported its efficacy and complications and compared the efficacy of RFA relative to other ablative options such as ethanol ablation and laser ablation.

scholarly journals Correction to: Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

2018 ◽  
Vol 25 (S3) ◽  
pp. 998-998
Author(s):  
Barbara Schwartzberg ◽  
John Lewin ◽  
Osama Abdelatif ◽  
Jacqueline Bernard ◽  
Hanadi Bu-Ali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Laser Ablation ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Trial ◽  
Breast Cancer Mri ◽  
Percutaneous Laser Ablation
Sign in / Sign up

Export Citation Format

Share Document